Abstract
The management of severe bacterial sepsis is an integral part of intensive care medicine. Early and appropriate treatment with antimicrobials positively affects mortality and significantly reduces the time spent in both intensive care and the hospital. Drug choice is usually made on a “best guess” basis and instituted prior to receipt of appropriate blood, sputum, urine or drainage culture results. Bactericidal drugs should be given in combination, delivered by intravenous bolus and directed towards broad cover of all likely pathogens. Aminoglycoside/ureidopenicillin combinations are synergistic and widely used — often combined with metronidazole. Aminoglycoside toxicity can be reduced by giving the drug once daily (OD) rather than by traditional multiple daily dosing (MDD) and by measuring peak and trough serum levels. Efficacy is increased by attention to the peak serum level/MIC ratio which determines the response to treatment. Several newer agents have been more recently introduced. These drugs include ceftazidime, imipenem/cilastatin, the quinolones and clavulanic acid/semisynthetic penicillin combinations. Other newer drugs currently under evaluation include aztreonam, teicoplanin, the penems and carbapenems.
Article PDF
Similar content being viewed by others
References
Myers BR, Sherman E, Mendelson MH, Valesquez G, Srulevitch-Chin E, Hubbard M, Hirschmann SZ (1989) Bloodstream infections in the elderly. Am J Med 86:379
Kreger BE, Craven DE, McCabe WR (1980) Gram-negative bacteraemia. The evaluation of clinical features and treatment in 612 patients. Am J Med 68:344
Bone RC, Fisher CJ, Clemmer IP, Stonann GJ, Metz CA, Balh RA (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 12:389
L'a Force RM (1981) Hospital acquired Gram-negative rod pneumonias: an overview. Am J Med 70:664
Daschner FD, Frey P, Wolff G, Bannann PC, Suter P (1982) Nosocomial infections in intensive care wards: a multicentre prospective study. Intensive Care Med 8:5
Van Uffelen R, Rommes JH, Fidler V, van Saene HK (1987) Preventing lower airway colonisation and infection in mechanically ventilated patients. Crit Care Med 15:99
Smith CC (1986) Initial antibacterial therapy in patients with septicaemia. Res Clin Forums 8:7–15
Allan SG, Glover SC, Smith CC, Reid TMS (1983) An open study of ceftazidime in the treatment of serious bacterial infections. J Antimicrob Chemother 12:219–227
Imipenem/Cilastatin; monotherapy of hospital infections (1987) Scand J Infect Dis [Suppl 52]:5–78
Smith G (1988) Use of aztreonam in serious Gram-negative infections. J Antimicrob Chemother 21:233–241
Hawkey PM (1989) Where are we now with Ciprofloxacin? Leading article. J Antimicrob Chemother 24:477–479
Brogden RN, Heel RC (1986) Aztreonam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 31:96–130
Williams AH, Grüneberg RN (1988) Teicophanin revisited: leading article. J Antimicrob Chemother 22:392–399
Bryan CS, Reynolds KL, Brenner ER (1983) Analysis of 1186 episodes of Gram-negative bacteraemia in a non-university hospital: effects of antimicrobial therapy. Rev Infect Dis 5:629–638
Hata JS (1989) Infections in the critical care unit. Curr Opinion Infect Dis 25:659–662
Elliott TSJ (1988) Intravascular device infections. J Med Microbiol 27:161–167
Martin MA, Pfaller WA, Wenzel RP (1989) Coagulase-negative staphylococcal bacteraemia: mortality and hospital stay. Ann Intern Med 110:9–16
Moor RD, Smith CR, Wipshy JJ, Mellitis ED, Wietman PS (1984) Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100:352–357
Keller F, Borner K, Schwartz A, Offerman G, Node H (1987) Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit 9:148–153
Editorial (1986) Aminoglycoside toxicity. Lancet II:670–671
Chastre J, Fagon JY, Soler P, Bornet M, Domart Y, Tromiket JL, Gibert C, Hance AJ (1988) Diagnosis of nosocomial bacterial pneumonia in intubated patients undergoing ventilation: comparison of usefulness of bronchoalveolar lavage and the protected specimen brush. Am J Med 85:499–506
Craven DE, Kunches LM, Lichtenberg DA, Kollisch NR, Barry MA, Heeren TC, McCake WR (1988) Nosocomial infection and fatality in medical and surgical intensive care patients. Arch Intern Med 148:1161–1168
Stoutenbeek CP, van Saene HKF, Miranda DR, Zandstra DF (1984) The effect of selective decontamination of the digestive track on colonisation and infection rate in multiple trauma patients. Intensive Care Med 10:185–192
Ledingham IMcA, Alcock SR, Eastaway AT, McDonald JC, McKay IC, Ramsay G (1988) Triple regimen of selective decontamination of digestive tract, systemic cefotaxime and microbiological surveillance for prevention of acquired infection in intensive care. Lancet I:785–790
Moore RD, Smith CR, Wietman PS (1984) The association of aminoglycoside plasma levels with mortality in patients with gramnegative bacteraemia. J Infect Dis 149:443–448
John JF (1988) What price success? The continuing saga of the toxic/therapeutic ratio with aminoglycoside antibiotics. J Infect Dis 158:1–6
Drusano GL (1988) Role of pharmacokinetics in the outcome of infection. Antimicrob Agents Chemother 32:289–297
Moore RD, Wietman PS, Smitz CR (1987) Clinical response to aminoglycoside therapy: importance of ratio of peak concentration to MIC. J Infect Dis 155:93–99
Flint LM, Gott J, Short L, Richardson JD, Polk HC (1985) Serum level monitoring of aminoglycoside antibiotics. Arch Surg 120:99–102
Mattie H, Craig WA, Pechere JC (1989) Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 24:281–293
Sturm AW (1989) Netilmicin in the treatment of gram-negative bacteraemia — Single dose vs multiple daily dosing. J Infect Dis 159:931
Smith CC (1985) The penicillins and cephalosporins. In: Clinically important adverse drug interactions, vol 3. Elsevier, Amsterdam, pp 111–153
Richards DM, Brodgen RN (1985) Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 29:105–161
Graham J (1986) Imipenem in the treatment of severe bacterial infections in serious sick patients. J Antimicrob Chemother [Suppl E] 18:131–140
Robinson GN (1989) β-lactamase induction and resistance to β-lactam antibiotics. J Antimicrob Chemother 23:12
Clavulanate/β-lactam antibiotics: Further experience (1989). J Antimicrob Chemother [Suppl B] 24:1–221
Warnock DW (1989) Jtraconazole and fluconazole: new drugs for deep fungal infection. J Antimicrob Chemother 24:275–277
Van Wout JW, Mattie H, van Furth R (1988) A prospective study of the efficacy of fluconazole against deep seated fungal infections. J Antimicrob Chemother 21:665–672
Cytomegalovirus: the disease and its management (1989). J Antimicrob Chemother [Suppl E] 23:1–20
Cefmetazole: a clinical appraisal (1989). J Antimicrob Chemother [Suppl A] 23:1–131
Meropenem: a new carbapenem (1989). J Antimicrob Chemother [Suppl A] 24:1–311
Zaske DE, Cipolle RJ, Rotschager JC (1982) Gentamicin pharmacokinetics in 1640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 30:78
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, C.C. Treatment of sepsis in an intensive care unit. Intensive Care Med 16 (Suppl 3), S243–S247 (1990). https://doi.org/10.1007/BF01709709
Issue Date:
DOI: https://doi.org/10.1007/BF01709709